{
    "clinical_study": {
        "@rank": "40337", 
        "acronym": "ATLANTIC", 
        "arm_group": {
            "arm_group_label": "MEDI4736", 
            "arm_group_type": "Experimental", 
            "description": "see below"
        }, 
        "brief_summary": {
            "textblock": "A study to assess the Effects of MEDI4736 in Patients With Locally Advanced or Metastatic\n      Non Small Cell Lung Cancer in terms of efficacy, safety and tolerability"
        }, 
        "brief_title": "A Global Study to Assess the Effects of MEDI4736 in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer", 
        "completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Non-Small Cell Lung Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "This study is designed to investigate the efficacy, safety, tolerability of a new drug,\n      MEDI4736, in patients with Locally Advanced or Metastatic Non Small Cell Lung Cancer.\n      MEDI4736 will be investigated in patients who have received at least two prior treatment\n      regimens including one platinum-based chemotherapy"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Aged at least 18 years.\n\n          -  Documented evidence of NSCLC (stage IIIB/IV disease)\n\n          -  Disease progression or recurrence after both a platinum-based chemotherapy and at\n             least 1 additional regimen for treatment of NSCLC\n\n          -  World Health Organisation (WHO) Performance Status of 0 or 1\n\n          -  Estimated life expectancy of more than 12 weeks\n\n        Exclusion Criteria:\n\n          -  Prior exposure to any anti-PD-1 or anti-PD-L1 antibody\n\n          -  Brain metastases or spinal cord compression or unless asymptomatic, treated and\n             stable (not requiring steroids).\n\n          -  Active or prior autoimmune disease or history of immunodeficiency\n\n          -  Evidence of severe or uncontrolled systemic diseases, including active bleeding\n             diatheses or active infections including hepatitis B, C and HIV.\n\n          -  Evidence of uncontrolled illness such as symptomatic congestive heart failure,\n             uncontrolled hypertension or unstable angina pectoris.\n\n          -  Any unresolved toxicity CTCAE >Grade 2 from previous anti-cancer therapy.\n\n          -  Any prior Grade \u22653 immune-related adverse event (irAE) while receiving any previous\n             immunotherapy agent, or any unresolved irAE >Grade 1\n\n          -  Active or prior documented inflammatory bowel disease (eg, Crohn's disease,\n             ulcerative colitis)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "210", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 4, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02087423", 
            "org_study_id": "D4191C00003"
        }, 
        "intervention": {
            "arm_group_label": "MEDI4736", 
            "description": "MEDI4736 by intravenous infusion every two weeks. Treatment from Day 1 for a maximum of 12 months or study drug withdrawal if this occurs earlier.", 
            "intervention_name": "MEDI4736", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Locally advanced, metastatic, Non-Small Cell Lung Cancer, MEDI4736, PD-L1", 
        "lastchanged_date": "March 24, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "LA", 
                        "country": "United States", 
                        "state": "California"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tampa", 
                        "country": "United States", 
                        "state": "Florida"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Huntersville", 
                        "country": "United States", 
                        "state": "North Carolina"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Canton", 
                        "country": "United States", 
                        "state": "Ohio"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Spokane", 
                        "country": "United States", 
                        "state": "Washington"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase II,Non-comparative,Open Label, Multi-centre, International Study of MEDI4736, in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIB-IV) Who Have Received at Least 2 Prior Systemic Treatment Regimens Including 1 Platinum-based Chemotherapy Regimen", 
        "overall_contact": {
            "email": "ClinicalTrialTransparency@astrazeneca.com", 
            "last_name": "AstraZeneca Clinical Study Information", 
            "phone": "800-236-9933"
        }, 
        "overall_official": {
            "affiliation": "AstraZeneca", 
            "last_name": "Paul Stockman, MBChB, PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "Canada: Health Canada", 
                "Japan: Pharmaceuticals and Medical Devices Agency", 
                "South Korea: Korea Food and Drug Administration (KFDA)", 
                "Czech Republic: State Institute for Drug Control", 
                "Belgium: Federal Agency for Medicinal Products and Health Products", 
                "Germany: Paul-Ehrlich-Institut", 
                "Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products", 
                "France: ANSM, The French National Agency for Medicines and Health Products Safety", 
                "Philippines: Department of Health", 
                "Austria: Federal Office for Safety in Health Care", 
                "Malaysia: Ministry of Health", 
                "Italy: The Italian Medicines Agency"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Objective response rate (ORR) using Independent Central Review assessments according to RECIST 1.1", 
            "safety_issue": "No", 
            "time_frame": "Screening up to 2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02087423"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Duration of response (DoR) using Independent Central Review assessments according to RECIST 1.1", 
                "safety_issue": "No", 
                "time_frame": "Screening up to 2 years"
            }, 
            {
                "measure": "Progression Free survival (PFS) using Independent Central Review assessments according to RECIST 1.1", 
                "safety_issue": "No", 
                "time_frame": "Screening up to 2 years"
            }, 
            {
                "measure": "Disease control rate (DCR) using Independent Central Review assessments according to RECIST 1.1", 
                "safety_issue": "No", 
                "time_frame": "Screening up to 2 years"
            }, 
            {
                "measure": "Overall Survival (OS, death due to any cause)", 
                "safety_issue": "No", 
                "time_frame": "Screening up to 2 years"
            }, 
            {
                "measure": "Deep sustained response (DSR) using Independent Central Review assessments according to RECIST 1.1", 
                "safety_issue": "No", 
                "time_frame": "Screening up to 2 years"
            }, 
            {
                "measure": "Levels of Anti-Drug Antibody (ADA) in patients treated with MEDI4736", 
                "safety_issue": "No", 
                "time_frame": "Day 1 up to 2 years"
            }, 
            {
                "measure": "Levels of tumoural expression of PD-L1", 
                "safety_issue": "No", 
                "time_frame": "Screening up to 2 years"
            }, 
            {
                "measure": "Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "Screening up to 2 years"
            }, 
            {
                "measure": "Vital signs (blood pressure and pulse)", 
                "safety_issue": "Yes", 
                "time_frame": "Screening up to 2 years"
            }, 
            {
                "measure": "Electrocardiograms", 
                "safety_issue": "Yes", 
                "time_frame": "Screening up to 2 years"
            }, 
            {
                "measure": "Physical examinations", 
                "safety_issue": "Yes", 
                "time_frame": "Screening up to 2 years"
            }, 
            {
                "measure": "Laboratory findings (clinical chemistry, haematology)", 
                "safety_issue": "Yes", 
                "time_frame": "Screening up to 2 years"
            }, 
            {
                "measure": "Laboratory findings (urinalysis)", 
                "safety_issue": "Yes", 
                "time_frame": "Screening up to 2 years"
            }, 
            {
                "measure": "Concentration of MEDI4736 in blood and non compartmental PK parameters (peak)", 
                "safety_issue": "No", 
                "time_frame": "Day 1 up to 2 years"
            }, 
            {
                "measure": "Concentration of MEDI4736 in blood and non compartmental PK parameters (trough)", 
                "safety_issue": "No", 
                "time_frame": "Day 1 up to 2 years"
            }
        ], 
        "source": "AstraZeneca", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AstraZeneca", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}